Insight Molecular Diagnostics (IMDX) Q2 FY26 earnings call

Insight Molecular Diagnostics is nearing FDA marketing authorization for its GraftAssureDx transplant rejection test, supported by favorable market dynamics including expanded Medicare reimbursement and strong clinical data. The company is managing cash burn while investing ahead of commercial launch, aiming for profitability. They are also progressing with IVDR submission and exploring TAM expansion beyond kidney transplants.